CoChat
Cited by 12

The DOI matches its Crossref record.

LL37-Derived Fragments Improve the Antibacterial Potential of Penicillin G and Ampicillin against Methicillin-Resistant Staphylococcus aureus

Han, Wenxu, Camesano, Terri A. · 2023 · Antibiotics

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infections are a severe threat to public health. Antimicrobial peptides (AMPs) are novel and potential antimicrobials with specific antibacterial mechanisms. Our aim was to study the potential of LL37, FK16, and FK13 to enhance the anti-MRSA activity of antibiotics in vitro, particularly penicillin G and ampicillin. Our results showed that FK16 and FK13 have more synergistic inhibitory effects to MRSA strains when combined with penicillin G and ampicillin. In addition, AMPs exhibited strong membrane permeabilizing properties, and membrane permeabilizing effects can provide a possible explanation for the improved antibacterial effects of antibiotics, since permeabilizing AMPs have the potential to increase the access of antibiotics. To further study the electrostatic interactions among cationic AMPs with negatively charged bacteria, we measured the zeta potentials of three MRSA strains and also neutralized three MRSA strains with the addition of cationic AMPs. Further, we demonstrated the connection between membrane permeabilization and zeta potential neutralization. Finally, we treated MRSA strains with AMPs and characterized the MICs of penicillin G and ampicillin. FK16 was the most promising AMP among the three AMPs, since exposure to FK16 decreased the MICs of both penicillin G and ampicillin for all MRSA strains and also demonstrated more synergistic combinations when combined with antibiotics. AMP exposure and subsequent membrane permeabilization provide a possible pathway to re-sensitize drug-resistant bacteria to traditional antibiotics. Re-sensitization may help preserve the effectiveness of traditional antibiotics, thus providing a potential new strategy for fighting MRSA infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antibiotics12091398

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 57

  1. Awad, 2009, Implementation of a methicillin-resistant Staphylococcus aureus (MRSA) prevention bundle results in decreased MRSA surgical site infections, Am. J. Surg., 198, 607, 10.1016/j.amjsurg.2009.07.010 · doi:10.1016/j.amjsurg.2009.07.010
  2. Fishovitz, 2014, Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus, IUBMB Life, 66, 572, 10.1002/iub.1289 · DOI · Paper page
  3. Macheboeuf, 2006, Penicillin binding proteins: Key players in bacterial cell cycle and drug resistance processes, FEMS Microbiol. Rev., 30, 673, 10.1111/j.1574-6976.2006.00024.x · DOI · Paper page
  4. Kocaoglu, 2013, Penicillin-binding protein imaging probes, Curr. Protoc. Chem. Biol., 5, 239, 10.1002/9780470559277.ch130102 · DOI
  5. Hartman, 1984, Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus, J. Bacteriol., 158, 513, 10.1128/jb.158.2.513-516.1984 · DOI · Paper page
  6. Cong, 2020, Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features, J. Adv. Res., 21, 169, 10.1016/j.jare.2019.10.005 · DOI · Paper page
  7. Gu, 2013, The emerging problem of linezolid-resistant Staphylococcus, J. Antimicrob. Chemother., 68, 4, 10.1093/jac/dks354 · DOI · Paper page
  8. Bababeygy, 2009, Rifampin and linezolid in the treatment of methicillin-resistant Staphylococcus aureus preseptal cellulitis, Ophthalmic Plast. Reconstr. Surg., 25, 227, 10.1097/IOP.0b013e3181a394ab · DOI
  9. Tyers, 2019, Drug combinations: A strategy to extend the life of antibiotics in the 21st century, Nat. Rev. Microbiol., 17, 141, 10.1038/s41579-018-0141-x · DOI · Paper page
  10. Cadena, 2011, Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 55, 5430, 10.1128/AAC.00706-11 · DOI
  11. Liu, 2020, Effect of tolerance on the evolution of antibiotic resistance under drug combinations, Science, 367, 200, 10.1126/science.aay3041 · DOI · Paper page
  12. Hegreness, 2008, Accelerated evolution of resistance in multidrug environments, Proc. Natl. Acad. Sci. USA, 105, 13977, 10.1073/pnas.0805965105 · DOI · Paper page
  13. Mohammad, 2015, Antimicrobial peptides and peptidomimetics-potent therapeutic allies for staphylococcal infections, Curr. Pharm. Des., 21, 2073, 10.2174/1381612821666150310102702 · DOI
  14. Halder, 2015, Alteration of Zeta potential and membrane permeability in bacteria: A study with cationic agents, SpringerPlus, 4, 672, 10.1186/s40064-015-1476-7 · DOI · Paper page
  15. Chan, 2006, Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action, Biochim. Biophys. Acta, 1758, 1184, 10.1016/j.bbamem.2006.04.006 · DOI · Paper page
  16. Lei, 2019, The antimicrobial peptides and their potential clinical applications, Am. J. Transl. Res., 11, 3919
  17. Assoni, 2020, Resistance mechanisms to antimicrobial peptides in gram-positive bacteria, Front. Microbiol., 11, 2362, 10.3389/fmicb.2020.593215 · DOI · Paper page
  18. Normark, 2002, Evolution and spread of antibiotic resistance, J. Intern. Med., 252, 91, 10.1046/j.1365-2796.2002.01026.x · DOI · Paper page
  19. Roemhild, R., and Andersson, D.I. (2021). Mechanisms and therapeutic potential of collateral sensitivity to antibiotics. PLoS Pathog., 17. · DOI
  20. Kahlenberg, 2013, Little peptide, big effects: The role of LL-37 in inflammation and autoimmune disease, J. Immunol., 191, 4895, 10.4049/jimmunol.1302005 · DOI · Paper page
  21. Sudheendra, 2006, LL-37, the only human member of the cathelicidin family of antimicrobial peptides, Biochim. Biophys. Acta (BBA) Biomembr., 1758, 1408, 10.1016/j.bbamem.2006.03.030 · DOI · Paper page
  22. Mahlapuu, 2014, Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: A randomized, placebo-controlled clinical trial, Wound Repair Regen., 22, 613, 10.1111/wrr.12211 · DOI · Paper page
  23. Lozeau, 2018, Concentration-dependent, membrane-selective activity of human LL37 peptides modified with collagen binding domain sequences, Biomacromolecules, 19, 4513, 10.1021/acs.biomac.8b00802 · doi:10.1021/acs.biomac.8b00802
  24. Han, 2022, New antimicrobial peptide-antibiotic combination strategy for Pseudomonas aeruginosa inactivation, Biointerphases, 17, 041002, 10.1116/6.0001981 · doi:10.1116/6.0001981
  25. Ridyard, K.E., and Overhage, J. (2021). The potential of human peptide LL-37 as an antimicrobial and anti-biofilm agent. Antibiotics, 10. · DOI · Paper page
  26. Wang, 2019, Design of antimicrobial peptides: Progress made with human cathelicidin LL-37, Antimicrob. Pept. Basics Clin. Appl., 1117, 215, 10.1007/978-981-13-3588-4_12 · DOI
  27. Li, 2006, Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region, J. Am. Chem. Soc., 128, 5776, 10.1021/ja0584875 · DOI · Paper page
  28. Mohamed, 2016, Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus, Sci. Rep., 6, 29707, 10.1038/srep29707 · DOI · Paper page
  29. Turner, 1998, Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob, Agents Chemother., 42, 2206, 10.1128/AAC.42.9.2206 · DOI · Paper page
  30. Mohammed, 2019, Cathelicidin-derived synthetic peptide improves therapeutic potential of vancomycin against Pseudomonas aeruginosa, Front. Microbiol., 10, 2190, 10.3389/fmicb.2019.02190 · DOI
  31. Geitani, R., Ayoub Moubareck, C., Touqui, L., and Karam Sarkis, D. (2019). Cationic antimicrobial peptides: Alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol., 19. · DOI
  32. Kondo, 1991, Susceptibility of methicillin-resistant Staphylococcus aureus to various antibiotics. Classification by aminoglycoside-modifying enzymes and antibiotics active against MRSA, Jpn. J. Antibiot., 44, 1211
  33. Ma, 2020, Contemporaneous Measurement of Outer and Inner Membrane Permeability in Gram-negative Bacteria, Bio-Protocol, 10, e3548, 10.21769/BioProtoc.3548 · DOI
  34. Rosenberg, 2019, Propidium iodide staining underestimates viability of adherent bacterial cells, Sci. Rep., 9, 6483, 10.1038/s41598-019-42906-3 · DOI · Paper page
  35. Lambert, 2002, Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria, J. Appl. Microbiol., 92, 46S, 10.1046/j.1365-2672.92.5s1.7.x · DOI · Paper page
  36. Maillard, 2021, Zeta potential beyond materials science: Applications to bacterial systems and to the development of novel antimicrobials, Biochim. Biophys. Acta (BBA) Biomembr., 1863, 183597, 10.1016/j.bbamem.2021.183597 · DOI
  37. Alves, 2010, Escherichia coli cell surface perturbation and disruption induced by antimicrobial peptides BP100 and pepR, J. Biol. Chem., 285, 27536, 10.1074/jbc.M110.130955 · DOI · Paper page
  38. Burgess, 2014, Amplified origins of antibiotic resistance, Nat. Rev. Genet., 15, 362, 10.1038/nrg3740 · DOI
  39. Azhar, 2017, Detection of high levels of resistance to linezolid and vancomycin in Staphylococcus aureus, J. Med. Microbiol., 66, 1328, 10.1099/jmm.0.000566 · doi:10.1099/jmm.0.000566
  40. Tian, Y., Li, T., Zhu, Y., Wang, B., Zou, X., and Li, M. (2014). Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China. BMC Microbiol., 14. · DOI
  41. Cui, 2003, Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus, J. Clin. Microbiol., 41, 5, 10.1128/JCM.41.1.5-14.2003 · DOI · Paper page
  42. Cui, 2021, Cell wall thickness and the molecular mechanism of heterogeneous vancomycin-intermediate Staphylococcus aureus, Lett. Appl. Microbiol., 72, 604, 10.1111/lam.13456 · doi:10.1111/lam.13456
  43. Field, 2016, Synergistic nisin-polymyxin combinations for the control of Pseudomonas biofilm formation, Front. Microbiol., 7, 1713, 10.3389/fmicb.2016.01713 · DOI
  44. Ejim, 2011, Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy, Nat. Chem. Biol., 7, 348, 10.1038/nchembio.559 · DOI · Paper page
  45. Swoboda, 2010, Wall teichoic acid function, biosynthesis, and inhibition, Chembiochem, 11, 35, 10.1002/cbic.200900557 · DOI · Paper page
  46. Brown, 2013, Wall teichoic acids of gram-positive bacteria, Annu. Rev. Microbiol., 67, 313, 10.1146/annurev-micro-092412-155620 · DOI · Paper page
  47. Giuliani, 2008, Antimicrobial peptides: Natural templates for synthetic membrane-active compounds, Cell. Mol. Life Sci., 65, 2450, 10.1007/s00018-008-8188-x · DOI · Paper page
  48. Nguyen, 2011, The expanding scope of antimicrobial peptide structures and their modes of action, Trends Biotechnol., 29, 464, 10.1016/j.tibtech.2011.05.001 · DOI · Paper page
  49. Sato, 2006, Peptide–membrane interactions and mechanisms of membrane destruction by amphipathic α-helical antimicrobial peptides, Biochim. Biophys. Acta (BBA) Biomembr., 1758, 1245, 10.1016/j.bbamem.2006.02.021 · DOI · Paper page
  50. Li, 2012, Overview on the recent study of antimicrobial peptides: Origins, functions, relative mechanisms and application, Peptides, 37, 207, 10.1016/j.peptides.2012.07.001 · DOI · Paper page
  51. Marks, L.R., Clementi, E.A., and Hakansson, A.P. (2012). The Human Milk Protein-Lipid Complex HAMLET Sensitizes Bacterial Pathogens to Traditional Antimicrobial Agents. PLoS ONE, 7. · DOI
  52. Mishra, 2016, Anti-staphylococcal biofilm effects of human cathelicidin peptides, ACS Med. Chem. Lett., 7, 117, 10.1021/acsmedchemlett.5b00433 · DOI
  53. Wiegand, 2008, Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances, Nat. Protoc., 3, 163, 10.1038/nprot.2007.521 · DOI · Paper page
  54. Cha, 2014, Synergistic effect between cryptotanshinone and antibiotics against clinic methicillin and vancomycin-resistant Staphylococcus aureus, Evid. Based Complement. Altern. Med., 2014, 450572, 10.1155/2014/450572 · DOI
  55. Li, 2021, Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens, Commun. Biol., 4, 31, 10.1038/s42003-020-01511-1 · DOI
  56. Ng, 2018, Rational design and synthesis of modified teixobactin analogues: In vitro antibacterial activity against Staphylococcus aureus, Propionibacterium acnes and Pseudomonas aeruginosa, Chem. A Eur. J., 24, 9136, 10.1002/chem.201801423 · DOI
  57. Kwon, 2019, Mechanism of action of antimicrobial peptide P5 truncations against Pseudomonas aeruginosa and Staphylococcus aureus, AMB Express, 9, 122, 10.1186/s13568-019-0843-0 · doi:10.1186/s13568-019-0843-0

Cited by

See all 12

Metadata

Authors
Han, W., & Camesano, T. A.
Venue
Antibiotics
Publisher
MDPI AG
Published
2023-09-01
Volume
12
Issue
9
Pages
1398
ISSN
2079-6382
Cited by
12
References
0
Language
en
Funders
ALDEN FELLOWSHIP from Worcester Polytechnic Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LL37-Derived Fragments Improve the Antibacterial Potential of Penicillin G and Ampicillin against Methicillin-Resistant Staphylococcus aureus. https://app.cochat.ai/papers/10.3390/antibiotics12091398
The paper
Han, W., & Camesano, T. A. (2023). LL37-Derived Fragments Improve the Antibacterial Potential of Penicillin G and Ampicillin against Methicillin-Resistant Staphylococcus aureus. Antibiotics. https://doi.org/10.3390/antibiotics12091398

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.